
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:27029</ns1:identifier>
    <ns1:title language="sr">Ispitivanje efikasnosti i bezbednosti kombinovane sistemske i lokalne kortikosteroidne terapije u lečenju teških formi alopecije areate kod dece</ns1:title>
    <ns2:subtitle language="sr">doktorska disertacija</ns2:subtitle>
    <ns2:alt_title language="en">The efficacy and safety of combined systemic and topical corticosteroid therapy in the treatment of severe alopecia areata in children : doctoral dissertation</ns2:alt_title>
    <ns1:language>sr</ns1:language>
    <ns1:description language="sr">Alopecia areata (AA) je autoimunsko oboljenje u čijem lečenju nema opšteprihvaćenihprotokola. Dugotrajna primena sistemskih kortikosteroida, iako terapijski efikasna, sa sobompotencijalno nosi niz neželjenih efekata.Cilj:Ispitati efekte različitih modaliteta pulsne kortikosteroidne terapije u kombinaciji sa lokalnomkortikosteroidnom terapijom na različite forme AA.Materijal i metode:U ispitivanje je uključeno 138 pacijenata sa AA, mlađih od 18 godina, sa zahvaćenošćukapilicijuma (SALT) &gt;30%.Pacijenti su aplikovali lokalno 0,05% klobetazol propionat mast sa polietilenskom okluzijomnoću, a sistemski su primali ili jednodnevnu oralnu pulsnu terapiju (OPT), jednodnevnuintravensku (1IVP) ili trodnevnu intravensku pulsnu terapiju (3IVP). Dobar terapijski odgovordefinisan je kao porast terminalne dlake &gt;50% u odnosu na status pre uvođenja terapije.Pacijenti su praćeni najmanje 12 meseci po završetku terapijskog protokola.Rezultati:3IVP kod pacijenata sa SALT ≥50, daje statistički značajno bolji terapijski odgovor u poređenjusa 1IVP (61% prema 25%) i OPT (61% prema 26%). Dobri prognostički faktori, nezavisno odtipa pulsne terapije bili su blaža forma AA, trajanje AA &lt;6 meseci; dok je loš prognostički faktorbila pridružena autoimunska bolest štitaste žlezde. Kod pacijenata koji su na kraju terapijeimali porast ≥50%, odnosno ≥75% i kompletan porast, pri dugotrajnom praćenju zadržan jepostignuti efekat u 85, 84, i 65% slučajeva.Zaključci:3IVP pokazuje statistički signifikantno najbolje rezultate u poređenju sa ostalim modalitetimaterapije kod pacijenata sa SALT ≥50. Kod većine pacijenata sa SALT skorom &lt;50, efekat terapijeje bio održan i na dugoročnom praćenju (91%). Kod pacijenata čiji je inicijalni SALT bio ≥50,efekat terapije je bio najbolje održan kod 3IVP pacijenata (79%), potom kod 1IVP (60%), anajlošije kod OPT pacijenata (50%).</ns1:description>
    <ns1:description language="en">Alopecia areata (AA) is an autoimmune disease without widely accepted treatment protocols.Systemic steroids are effective, but their long-term use provokes numerous side-effects.Goal:To evaluate the effects of combined pulse corticosteroid therapy and topical corticosteroids insevere forms of AA.Material and methods:The study included 138 patients younger than 18 years. SALT score in all patients was &gt;30. Thepatients applied topical 0.05% clobetasol propionate ointment under plastic wrap occlusionovernight with either one-day oral pulse therapy (OPT), one-day intravenous pulse therapy(1IVP) or three-day intravenous pulse therapy (3IVP). Regrowth 50% of the initial status wasconsidered the good therapeutic outcome. Patients were followed at least for 12 months afterthe treatment completion.Results:3IVP in patients with SALT 50 had statistically significant higher percentage of goodtherapeutic outcomes in comparison with 1IVP (61% vs. 25%) and OPT patients (61% vs.26%). Good prognostic factors, independent of the type of pulse therapy, were: milder AA form,previous AA duration &lt;6 months. Bad prognostic factor was an associated thyroid autoimmunedisease. Patients who achieved terminal hair regrowth 50%, 75% and 100%, maintainedtheir status at the long-term follow-up in 85, 84 and 65% of patients, respectively.Conclusions:3IVP treatment protocol, in patients with SALT ≥50, achieved statistically significant betterresults in comparison with other pulse modalities. In patients with SALT score &lt;50, the effectsof therapy where maintained at the long-term follow-up (in 91%). In patients with SALT score≥50, the achieved hair growth was best maintained in the 3IVP group (79%), while in the 1IVPand OPT group, the achieved therapeutic effect was maintained in 60% and 50%, respectively.</ns1:description>
    <ns1:description language="sr">Medicina -  Medicinska farmakologija / Medicine- Medical pharmacology  Datum odbrane: 04.07.2022. </ns1:description>
    <ns1:keyword language="sr">alopecija areata, pulsna kortikosteroidna terapija, deca</ns1:keyword>
    <ns1:keyword language="en">alopecia areata, pulse corticosteroid therapy, children</ns1:keyword>
    <ns1:keyword language="sr">615.263.63:616.594.1-053.2(043.3)</ns1:keyword>
    <ns2:identifiers>
      <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>77964297</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552101</ns2:resource>
      <ns2:identifier>8835</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2022-11-22T10:12:14.053Z</ns1:upload_date>
    <ns1:status>45</ns1:status>
    <ns2:peer_reviewed>no</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname> Jovan, 1986-</ns3:firstname>
        <ns3:lastname>Lalošević</ns3:lastname>
        <ns3:conor>89089801</ns3:conor>
      </ns1:entity>
      <ns1:date>2022</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Miloš, 1961-</ns3:firstname>
        <ns3:lastname>Nikolić</ns3:lastname>
        <ns3:conor>12575847</ns3:conor>
      </ns1:entity>
      <ns1:date>2022</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Gordana, 1972-</ns3:firstname>
        <ns3:lastname>Dragović-Lukić</ns3:lastname>
        <ns3:conor>12836199</ns3:conor>
      </ns1:entity>
      <ns1:date>2022</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Ljiljana, 1962-</ns3:firstname>
        <ns3:lastname>Gojković-Bukarica</ns3:lastname>
        <ns3:conor>12592743</ns3:conor>
      </ns1:entity>
      <ns1:date>2022</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Mirjana, 1970-</ns3:firstname>
        <ns3:lastname>Gajić-Veljić</ns3:lastname>
        <ns3:conor>93068553</ns3:conor>
      </ns1:entity>
      <ns1:date>2022</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="5">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Dragan, 1966-</ns3:firstname>
        <ns3:lastname>Jovanović</ns3:lastname>
        <ns3:conor>3987047</ns3:conor>
      </ns1:entity>
      <ns1:date>2022</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>78, [21] str.</ns1:format>
    <ns1:size>6414110</ns1:size>
    <ns1:location>http://phaidrabg.bg.ac.rs/o:27029</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>12</ns1:license>
  </ns1:rights>
  <ns1:annotation>
    <ns6:annotations>
      <ns6:date>2022-11-22T10:12:14.320Z</ns6:date>
    </ns6:annotations>
  </ns1:annotation>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:taxonpath>
      <ns7:source>11</ns7:source>
      <ns7:taxon seq="0">1066950</ns7:taxon>
      <ns7:taxon seq="1">1067004</ns7:taxon>
    </ns7:taxonpath>
    <ns7:keyword language="sr" seq="0">alopecija areata, pulsna kortikosteroidna terapija, deca</ns7:keyword>
    <ns7:keyword language="sr" seq="1">alopecia areata, pulse corticosteroid therapy, children</ns7:keyword>
    <ns7:keyword language="sr" seq="2">615.263.63:616.594.1-053.2(043.3)</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1738</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>11A32</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:releaseyear>2022</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
